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OBJECTIVES The Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in
Heart Failure (IMPACT-HF) trial was an investigator-initiated study to evaluate if
predischarge carvedilol initiation in stabilized patients hospitalized for heart failure (HF)
increased the number of patients treated with beta-blockade at 60 days after randomization
without increasing side effects or length of hospital stay.
BACKGROUND Beta-blockers are underused in HF. Predischarge initiation may improve the use of
evidence-based beta-blockade.
METHODS The IMPACT-HF was a prospective, randomized open-label trial conducted in 363 patients
hospitalized for HF. Patients were randomized to carvedilol initiation pre-hospital discharge
or to postdischarge initiation (2 weeks) of beta-blockade at the physicians’ discretion. The
primary end point of the study was the number of patients treated with beta-blockade at 60
days after randomization. Secondary end points included the number of patients discontinu-
ing beta-blockade, median dose achieved, and a composite of death, rehospitalization,
unscheduled visit for HF, or 50% increase in oral diuretic, new oral diuretic, or any
intravenous therapy with diuretics, inotropes, or other vasoactive agents.
RESULTS At 60 days 165 patients (91.2%) randomized to predischarge carvedilol initiation were treated
with a beta-blocker, compared with 130 patients (73.4%) randomized to initiation postdis-
charge (p  0.0001). Predischarge initiation was not associated with an increased risk of
serious adverse events. The median length of stay was five days in both groups.
CONCLUSIONS Predischarge initiation of carvedilol in stabilized patients hospitalized for HF improved the
use of beta-blockade at 60 days without increasing side effects or length of stay. Predischarge
initiation may be one approach to improve beta-blocker use in this population. (J Am Coll
Cardiol 2004;43:1534–41) © 2004 by the American College of Cardiology Foundationa
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wata from clinical trials have confirmed the role of specific
eta-blockers (carvedilol, metoprolol succinate XL, bisopro-
ol) in the management of mild, moderate, and severe heart
ailure (HF) (1–3). The most recent American College of
ardiology/American Heart Association and the Heart
ailure Society of America (HFSA) HF guidelines recom-
end the use of beta-blockade in all patients with chronic
F and reduced systolic function who are without contra-
ndications to beta-blockers (4,5). The HFSA guidelines
ecommend that, in general, beta-blockers should not be
outinely initiated during a hospitalization for worsening
F (5).
Despite the substantial body of evidence demonstrating
he lifesaving benefits of beta-blockade as HF treatment,
hese drugs are underprescribed in the majority of patients
6,7). New strategies are clearly needed to identify effective
ethods of improving the use of evidence-based therapies
ecause hospitalizations for worsening HF are occurring at
From the *Division of Cardiology, Duke University Medical Center and Duke
linical Research Institute, Durham, North Carolina; and †Division of Cardiology,
orthwestern University/Feinberg School of Medicine, Chicago, Illinois. The
MPACT-HF trial was funded by GlaxoSmithKline, Philadelphia, Pennsylvania.
Manuscript received August 15, 2003; revised manuscript received November 30,d003, accepted December 2, 2003.n alarming rate, with more than three million patients
dmitted annually with a primary or secondary HF diagno-
is (8). The Initiation Management Predischarge: Process
or Assessment of Carvedilol Therapy in Heart Failure
IMPACT-HF) trial was an investigator-initiated protocol
esigned to evaluate whether a strategy of carvedilol initia-
ion pre-hospital discharge would be effective at improving
he use of beta-blockade at 60 days post-randomization
ithout increasing side effects or length of initial hospital
tay in patients hospitalized for HF.
ETHODS
he Duke University Cooperative Cardiovascular Studies
DUCCS) investigators conducted the study. The trial
perations, site management, data management, and statis-
ical analyses were performed independently of the study
ponsor by the Duke Clinical Research Institute (DCRI).
he IMPACT-HF study was a prospective, randomized
pen-label trial of carvedilol initiation predischarge com-
ared with standard practice, which was defined as postdis-
harge initiation of any beta-blocker no earlier than two
eeks after discharge at the physician’s discretion. The
etailed study design has been published (9). The study
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May 5, 2004:1534–41 Carvedilol in Heart Failure Predischargenrolled 363 patients from 45 centers across the U.S.
atients could enter the study if they had left ventricular
jection fraction 40% and were hospitalized with a pri-
ary diagnosis of HF. Patients were ineligible if they met
ny of the following criteria: treatment with any beta-
locker within 30 days before randomization; decompen-
ated New York Heart Association functional class IV HF
equiring inotropic support at randomization; second- or
hird-degree atrioventricular block, sick sinus syndrome, or
ymptomatic bradycardia without a functional pacemaker;
ronchial asthma or related bronchospastic conditions;
ymptomatic hypotension defined by the investigator; car-
iogenic shock; expected survival60 days; hypersensitivity
o carvedilol; clinically manifest hepatic impairment; or
eing pregnant or lactating. The protocol was reviewed and
pproved by the Data Safety Monitoring Board (DSMB)
nd the local institutional review board at each institution.
ll patients provided written informed consent.
Patients were randomized 1:1 using an interactive voice-
ecognition system to receive either carvedilol initiation
redischarge (3.125 mg twice daily) or beta-blocker initia-
ion postdischarge at the physician’s discretion. Patients
andomized to carvedilol initiation predischarge could re-
eive carvedilol at any point after the principal investigator
eemed the patient to be stable from a HF standpoint, but
o later than 12 h before discharge. The goal was to
dminister at least one dose before discharge. The postdis-
harge initiation arm was based on HFSA HF practice
uidelines (5). These guidelines recommended waiting at
east two weeks post-hospital discharge before initiating
eta-blockade. In this group, physicians could choose
hether or not to institute beta-blocker therapy at their
iscretion provided it was at least two weeks after hospital
ischarge. Physicians were not required per protocol to see
atients in clinic at two weeks post-discharge, nor were they
equired to initiate beta-blockade at two weeks postdis-
harge. It was up to the physician’s discretion to determine
he appropriate time of follow-up for each patient in both
roups, and it was the physician’s choice to determine when
nd if to initiate beta-blockade in the postdischarge initia-
ion arm. The protocol did not mandate which beta-blocker
hould be prescribed in this group; however, the protocol
ecommended that only those beta-blockers with a Food
nd Drug Administration-approved indication for HF
Abbreviations and Acronyms
ADHERE  Acute Decompensated Heart Failure
National Registry
DCRI  Duke Clinical Research Institute
DSMB  Data Safety Monitoring Board
HF  heart failure
HFSA  Heart Failure Society of America
IMPACT-HF  Initiation Management Pre-Discharge:
Assessment of Carvedilol Therapy for
Heart Failurecarvedilol or metoprolol succinate XL) should be used. The
ponsor did not communicate with the investigators to
nfluence the use of beta-blockers in the study groups. All
ite contact was made by the DCRI. Patients in both groups
ere contacted by the study coordinator at 30 and 60 days
fter randomization to determine the patient’s current
edical regimen. Detailed information on beta-blocker
nitiation, titration, and discontinuation was collected. The
ccurrence of clinical events was also documented. The
ethod of contact (i.e., telephone, in-clinic) was deter-
ined by each site in the trial. Patients were not required
er protocol to be evaluated in clinic at specified time
oints.
The primary end point of the study was the number of
atients treated with any beta-blocker at 60 days after
andomization. Several secondary end points were also
respecified, including median beta-blocker dose pre-
cribed; number of patients requiring discontinuation of
eta-blockade; median time to discontinuation of beta-
lockade; and a composite end point of time to death,
ecurrent hospitalization, unscheduled visit for HF, 50%
ncrease in oral diuretic therapy, addition of new oral
iuretic therapy excluding spironolactone, or any intrave-
ous therapy with diuretics, inotropes, inodilators, or other
asoactive agents within 60 days post-randomization.
All nonserious adverse events and serious adverse events
ere reported to the DCRI Safety Desk. An independent
SMB reviewed all serious adverse events in this study at
respecified time points. At each review point, the DSMB
llowed the trial to continue.
The calculated sample size for the study was based on
everal assumptions. It was estimated that 35% of patients
andomized to the physician-discretion postdischarge initi-
tion arm would be treated with beta-blockers at 60 days,
nd the predischarge initiation of carvedilol would increase
he use of beta-blockers at 60 days to 50%. At an alpha level
f 0.05, 375 patients would provide 80% power to detect a
ignificant difference in the rate of beta-blocker use between
roups.
As the study was nearing completion, the sample size
stimates were reevaluated using the pooled blinded rate of
eta-blocker use in the study population. This analysis
emonstrated the study had adequate power with 360
atients to detect a significant difference as small as 17%
etween treatment groups. Thus, enrollment was closed
fter 363 patients had been enrolled.
tatistical methods. Statistical analyses were performed
sing SAS Version 8.2 on the UNIX system (SAS Institute,
ary, North Carolina). The Pearson chi-square test was
sed to evaluate the primary end point. Secondary end
oints represented as continuous variables were analyzed
sing the Wilcoxon rank-sum test. The secondary end
oints represented as proportions were analyzed using the
earson chi-square test. Fisher’s exact test was used to test
ifferences in death alone and differences in unscheduled visits
or HF alone because the number of these events was small.
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Carvedilol in Heart Failure Predischarge May 5, 2004:1534–41aplan-Meier survival curves were produced for the primary
omposite as well as 60-day death  rehospitalization.
For a difference in proportions between the randomized
roups for beta-blocker use at 60 days and clinical events at
0 days, 95% confidence intervals were calculated. The
ariance was calculated for each proportion to obtain the
tandard error of the difference. This standard error was
hen used to calculate 95% asymptotic confidence limits of
he difference using the normal approximation to the
inomial.
ESULTS
total of 363 patients were enrolled into the IMPACT-HF
rial (Fig. 1). The first patient was enrolled in May 2001. The
ast patient follow-up was October 2002. The majority of
atients were cared for by community-based cardiologists, with
smaller percentage of patients cared for by internal or family
edicine. There was no difference in the distribution of
hysician type between groups. The median age was 67 years,
7% were women, and 35% were of minority ethnic origin.
he baseline demographics of the population were similar
etween groups (Table 1). The baseline clinical characteristics
Table 2) reflect a population of patients with evidence of
orsening HF and congestion on admission. The median time
rom admission to randomization was 60.9 h. The use of
tandard HF medication was similar between the predischarge
nitiation and postdischarge physician-discretion groups, re-
pectively: angiotensin-converting enzyme inhibitors (74.6%
s. 74.2%), angiotensin receptor blockers (8.6% vs. 6.2%),
igure 1. Study outline. Patients with reactive airway disease were ex-
luded per protocol, but patients with chronic obstructive pulmonary
isease were allowed. The investigator made the determination of pulmo-
ary disease too severe for the patient to be enrolled. AV  atrioventric-
lar; EF  ejection fraction; HF  heart failure; NYHA  New York
eart Association.igoxin (50.8% vs. 42.1%), diuretic (80% vs. 82.6%), spirono- tactone (27% vs. 28.1%). On average, symptoms of worsening
F and volume overload improved during the period from
dmission to randomization; however, patients still had some
vidence of congestion at the time of randomization, as
eflected by one-third of the population with rales. By the time
f discharge, patients’ symptoms of HF had improved but had
ot completely resolved (Table 2).
The primary analysis of the trial showed that patients
andomized to carvedilol initiation predischarge were more
ikely to be treated with any beta-blocker at 60 days as
ompared to patients randomized to the physician-
iscretion postdischarge beta-blocker initiation arm (91.2%
s. 73.4%, p  0.0001) (Table 3). Patients were also more
ikely to reach a higher percentage of the target beta-blocker
ose if they were randomized to predischarge initiation as
ompared with those who were not (Table 4). The mean
ercentage of target dose achieved for the carvedilol initia-
ion group was 36.3% compared with 28.6% for the patients
n the postdischarge initiation arm. There was a difference
n the distribution of percentage of target beta-blocker
osage between the two treatment groups. A shift towards
arger percentages was seen in the predischarge carvedilol
nitiation arm when compared with the postdischarge ini-
iation arm (p  0.02). The median time to initiation of a
eta-blocker after randomization was 0 days for the carve-
ilol predischarge initiation group versus 17 days in the
ostdischarge beta-blocker initiation group. There appeared
o be no difference in the need for permanent beta-blocker
iscontinuation between the two groups, with 10.5% of
arvedilol predischarge initiation patients having their beta-
locker permanently discontinued during the 60 days of
ollow-up as compared with 10.6% of the postdischarge
eta-blocker initiation group. Of those patients who had
heir initial beta-blocker discontinued, patients in the arm
nitiated on a beta-blocker 2 weeks postdischarge discon-
able 1. Baseline Characteristics
Predischarge
Carvedilol
Initiation
(n  185)
Physician-
Discretion
Postdischarge
Initiation
(n  178)
edian age (25th, 75th) 68 (55, 77) 66 (52, 76)
ale (%) 97 (52.4) 96 (53.9)
aucasian (%) 118 (63.8) 116 (65.2)
schemic etiology (%) 71 (43.6) 78 (48.1)
edian LVEF (25th, 75th) 25 (20, 30) 25 (20, 30)
ypertension (%) 113 (61.1) 118 (66.3)
trial arrhythmia (%) 37 (20) 42 (23.6)
entricular arrhythmia (%) 15 (8.1) 18 (10.1)
yperlipidemia (%) 54 (29.2) 53 (29.8)
iabetes (%) 68 (36.8) 73 (41)
hronic renal insufficiency 20 (10.8) 20 (11.2)
ulmonary disease (%) 28 (15.1) 21 (11.8)
edian hours from admission
to randomization
(25th, 75th)
61.9 (30.9, 95.6) 60.0 (34.4, 108.8)
VEF  left ventricular ejection fraction.inued beta-blocker therapy sooner (8 days) as compared
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May 5, 2004:1534–41 Carvedilol in Heart Failure Predischargeith those patients randomized to carvedilol predischarge
nitiation (14 days), suggesting that predischarge initiation
as not associated with an early withdrawal rate due to
ntolerance or adverse effects. The rates of worsening HF,
ypotension, and bradycardia requiring drug discontinua-
ion were low and did not appear to be different between
roups (Table 5). Importantly, the length of hospital stay
as not increased in the predischarge initiation arm; the
edian (25th, 75th percentile) length of stay was five days
3,8) for both groups.
able 2. Heart Failure Signs and Symptoms
Predischarge Carvedilol Initiat
n  185
Admission Randomization
eight (kg) 80 (64, 95) 79 (65, 95)
ystolic blood pressure
(mm Hg)
135 (118, 150) 123 (107, 138)
iastolic blood pressure
(mm Hg)
79 (70, 89) 69 (60, 80)
eart rate (beats/min) 91 (78, 104) 84 (73, 94)
erum sodium (mmol/l) 139 (136, 141) 138 (136, 140)
erum creatinine (mol/l) 97.20 (79.6, 132.6) 97.2 (79.6, 132.6)
YHA functional class
I 8 (5) 13 (7.3)
II 47 (29.6) 59 (33.1)
III 70 (44) 86 (48.3)
IV 34 (21.4) 20 (11.2)
VD (%) 57 (35.2) 29 (17.2)
3 (%) 44 (24.4) 42 (22.7)
ales (%) 106 (57.9) 60 (32.8)
dema (%)
1 50 (49.5) 47 (66.2)
2 30 (29.7) 15 (21.1)
3 14 (13.9) 8 (11.3)
4 7 (6.9) 1 (1.4)
atigue (%)* 95 (51.9) 111 (60)
rthopnea (%)* 90 (49.2) 50 (27)
aroxysmal nocturnal
dyspnea (%)*
68 (37.2) 35 (18.9)
yspnea on exertion (%)* 145 (79.2) 146 (78.9)
yspnea at rest (%)* 75 (41) 47 (25.4)
alues are given as median (25th, 75th) percentiles or number (%). *Patients can be
JVD  jugular venous distention; NYHA  New York Heart Association.
Table 3. Beta-Blocker Use at 60 Days Postdisc
P
Patients treated with any beta-blocker at 60
days (%)
Carvedilol
Metoprolol succinate XL
Metoprolol tartrate IR
Atenolol
Any beta-blocker initiated (%)
‡Discontinued and restarted at least once (%)
Discontinued and never restarted (%)
*p  0.0001; †difference  physician discretion-carvedil
denominator for postdischarge initiation  141.CI  confidence interval.The study was not powered to detect significant differ-
nces in clinical outcomes; however, we evaluated a com-
osite clinical secondary end point as described in the
ethods section to assess whether predischarge initiation
ight have any early adverse effect. In the predischarge
arvedilol initiation arm, 45.4% of patients experienced the
omposite end point, as compared with 46.1% of patients
andomized to the postdischarge beta-blocker initiation arm
p  0.9). Each component of the composite was also
valuated separately, and there was no difference between
Physician-Discretion Postdischarge Initiation
n  178
scharge Admission Randomization Discharge
63, 92) 82 (70, 99) 81 (68, 99) 80 (66, 97)
107, 134) 136 (120, 159) 125 (110, 139) 121 (108, 135)
60, 76) 80 (70, 95) 70 (60, 82) 70 (61, 78)
70, 86) 90 (81, 106) 83 (74, 94) 81 (72, 89)
ND 138 (135, 141) 138 (135, 140) ND
ND 106.1 (79.6, 132.6) 106.1 (79.6, 132.6) ND
12.4) 14 (8.6) 15 (8.6) 28 (16.7)
46.7) 46 (28.2) 61 (35.1) 92 (54.8)
36.1) 77 (47.2) 86 (49.4) 47 (28)
4.7) 26 (16) 12 (6.9) 1 (0.6)
7.7) 46 (28.6) 21 (13) 6 (4.1)
12.6) 30 (17) 23 (13.2) 13 (7.6)
15.8) 97 (54.5) 55 (31.1) 16 (9.2)
86) 45 (47.9) 40 (52.6) 38 (76)
10) 27 (28.7) 25 (32.9) 10 (20)
2) 17 (18.1) 10 (13.2) 1 (2)
2) 5 (5.3) 1 (1.3) 1 (2)
56.8) 97 (54.5) 120 (67.4) 102 (57.3)
10.3) 90 (50.6) 63 (35.4) 24 (13.5)
3.8) 51 (28.7) 34 (19.1) 6 (3.4)
59.5) 141 (79.2) 130 (73) 102 (57.3)
7) 77 (43.3) 36 (20.2) 9 (5.1)
e counted.
e
edilol
ation
charge
185
Physician-
Discretion
Postdischarge
Initiation
n  178
95% CI for
Difference in
Proportions†
(91.2) 130 (73.4) 0.2542, 0.1
9 113
2 8
4 5
0 4
(100) 142 (79.8) 0.2613, 0.1432
(6.6) 8 (5.7) 0.0622, 0.0431
(10.5) 15 (10.6) 0.663, 0.0691
iation; ‡denominator for predischarge initiation  181;ion
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Carvedilol in Heart Failure Predischarge May 5, 2004:1534–41he groups for any of the individual components (Table 6).
nonsignificant trend towards a lower rate of the compos-
te of death or rehospitalization was observed for the
redischarge carvedilol initiation group as compared with
atients randomized to the postdischarge physician-
iscretion arm (Fig. 2). The time to first event in the main
omposite was longer, but not significantly, for patients
andomized to the predischarge carvedilol initiation group
22 days vs. 15.5 days, p  0.21). Thus, there was no
vidence of early worsening with predischarge carvedilol
nitiation based on the individual components or on the
omposite end point.
ISCUSSION
everal databases have demonstrated the underuse of beta-
lockers among HF patients. The recent IMPROVE-
ENT HF program was conducted in 15 Western Euro-
ean countries among 1,363 primary care physicians and
nrolled 11,062 patients. In this population, only 34% were
eceiving a beta-blocker and only 20% were receiving both
n angiotensin-converting enzyme inhibitor and a beta-
locker (6). The Acute Decompensated Heart Failure
able 4. Percent of Target Dose Achieved for Carvedilol,
isoprolol, Metoprolol Tartrate IR or Metoprolol Succinate XL
t Day 60
% of Beta-Blocker
Target Dosage
Carvedilol Initiation
Predischarge
n  165
Physician-Discretion
Postdischarge
Initiation
n  126
6.25% 3 (1.8) 4 (3.2)
12.5% 35 (21.2) 41 (32.5)
18.75% 8 (4.8) 2 (1.6)
25% 60 (36.4) 45 (35.7)
37.5% 2 (1.2) 0 (0)
50% 38 (23) 30 (23.8)
100% 19 (11.5) 4 (3.2)
ata are presented as n (%). Wilcoxon rank-sum produced a p value of 0.02. Target
ose for carvedilol 50 mg/day. Target dose for metoprolol tartrate IR or metoprolol
uccinate XL 200 mg/day. 6.25% of target  3.125 mg/day carvedilol; 12.5 mg/day
etoprolol tartrate IR or metoprolol succinate XL. 12.5% of target  6.25 mg/day
arvedilol; 25 mg/day metoprolol tartrate IR or metoprolol succinate XL. 18.75% of
arget  9.375 mg/day carvedilol; 37.5 mg/day metoprolol tartrate IR or metoprolol
uccinate XL. 25% of target  12.5 mg/day carvedilol; 50 mg/day metoprolol tartrate
R or metoprolol succinate XL. 37.5% of target  18.75 mg/day carvedilol; 75
g/day metoprolol tartrate IR or metoprolol succinate XL. 50% of target  25
g/day carvedilol; 100 mg/day metoprolol tartrate IR or metoprolol succinate XL.
00% of target  50 mg/day carvedilol; 200 mg/day metoprolol tartrate IR or
etoprolol succinate XL.
able 5. Withdrawal Due to Serious Adverse Events
Carvedilol Initiation
Predischarge
n  185
Physician-Discretion
Postdischarge
Initiation
n  178
ypotension (%) *3 (1.6) 1 (0.6)
radycardia (%) †3 (1.6) 0
orsening heart failure (%) 1 (0.5) 3 (1.7)
One patient with a serious adverse event attributed to hypotension also had
ew-onset atrial flutter with rapid ventricular response and one patient with a serious
dverse event attributed to hypotension was receiving milrinone. †One patient whopxperienced a serious adverse event attributed to bradycardia also had digoxin toxicity.ational Registry (ADHERE) is a prospective observa-
ional registry among 250 centers that will enroll more than
00,000 patients hospitalized with a principal diagnosis of
F. Preliminary data from this registry suggest that beta-
lockers are prescribed in only 47% of eligible patients at
dmission. The percentage of patients treated increased to
8% at discharge, an increase of only 11% (7,10).
There are several reasons for the underuse of beta-
lockade. First, standard practice guidelines have recom-
ended that beta-blocker initiation should be avoided in
atients with a recent decompensation or hospitalization for
F because of a concern that beta-blockers may worsen HF
ymptoms (5). Second, physicians may be reluctant to
nitiate beta-blockade in outpatients who appear to be stable
ecause of inexperience with the therapy, reluctance to
ontribute to polypharmacy, or lack of awareness about the
mportance of beta-blockade. Moreover, if the beta-blocker
as not started before hospital discharge, the primary care
hysician may believe that the patient was a poor candidate
or the drug and forgo initiating this lifesaving therapy
uring outpatient follow-up. Third, a lag time exists be-
ween the availability of clinical data and incorporation of
he data into clinical practice among practicing physicians
11,12). Regardless of the cause, the end result is that as
any as 60% of HF patients who are candidates for
eta-blockers are not receiving this lifesaving evidence-
ased therapy.
Beta-blocker use was significantly increased at one year in
atients randomized to a structured outpatient nurse-
acilitated program as compared with patients followed by
hysicians who only received education or notification of
heir patients’ eligibility for beta-blockade (67% vs. 27% vs.
6%, p  0.001) (13). The rate of beta-blocker use among
atients randomized to predischarge beta-blocker initiation
n the IMPACT-HF trial was higher at 60 days (91%) than
he reported rates of beta-blocker use in the study by Ansari
t al. (13) at 1 year and in other trials testing outpatient
pproaches to initiation. This observation suggests that the
ost effective strategy to improve beta-blocker use may be a
ombined intervention that initiates therapy before hospital
ischarge and continues with aggressive follow-up and dose
itration in the outpatient setting.
The results of the IMPACT-HF trial have several
mportant implications. The population was older, com-
osed of more women and patients of minority ethnic origin
han in previous randomized controlled trials, suggesting
hat a representative population was enrolled. In addition,
he overall 60-day rate of death or rehospitalization was
triking (25%) despite the use of background angiotensin-
onverting enzyme inhibitors, diuretics, and digoxin in the
ajority of patients. This finding may in part be due to the
act that many patients were discharged with symptoms of
ongestion. Although the objective of most HF hospital-
zations is to relieve congestion, the weight loss in this study
as relatively small. The protocol did not mandate how
hysicians should treat volume overload. Thus, the methods
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May 5, 2004:1534–41 Carvedilol in Heart Failure Predischargesed and extent to which patients were decongested in this
tudy may reflect how patients are routinely treated outside
f a clinical trial setting. It may also reflect the fact that
F-associated morbidity and mortality are excessively high
espite current treatments. Advancements in the medical
anagement of HF are still needed to reduce the burden-
ome rate of hospitalizations and other morbid events in this
atient population.
The IMPACT-HF data show that initiation of carvedilol
efore hospital discharge in appropriate patients is effective
t improving the use of beta-blockade at 60 days. The rate
f beta-blocker use in the predischarge initiation arm was
xtremely high, with 91% of patients receiving beta-blockade
t 60 days. The exclusion criteria for IMPACT-HF were
inimal and excluded only those patients who would have
ad a contraindication to carvedilol according to the Food
nd Drug Administration-approved product labeling. The
mplication of this finding is that the vast majority of HF
atients are candidates for and can tolerate carvedilol
herapy. The rate of beta-blocker use in the postdischarge
nitiation arm was also high; however, this usage rate is
ikely due in part to the open-label design of the
MPACT-HF trial. One would not expect to see this high
ate of beta-blocker use outside of a clinical trial testing this
pproach. Most recently, the ADHERE registry reported
hat only 47% of patients admitted to the hospital for
orsening HF were treated with a beta-blocker chronically
efore admission (7). These data are a more realistic
ndicator of the actual use of beta-blockade because the
DHERE registry is not subject to the open-label limita-
ions that were unavoidably present in the design of the
MPACT-HF trial.
Another important finding of the IMPACT-HF trial is
hat carvedilol could be initiated before discharge in patients
ospitalized for worsening HF without increasing the risk
f side effects and without increasing the length of initial
ospital stay. Although some data suggest that HF patients
lready on a beta-blocker may safely be continued on their
reexisting therapy during a hospitalization for worsening
ymptoms, no studies have been conducted to evaluate the
afety of initiation of beta-blockade in the hospitalized HF
atient (14). Standard guidelines recommended avoiding
Table 6. Clinical Events at 60 Days
Carvedilo
Predis
n 
Composite end point (%) 84 (
Death (%) 6 (
Rehospitalization (%) 40 (
Unscheduled visit for heart failure (%) 6 (
Change in heart failure therapy (%) 57 (
Death  rehospitalization (%) 44 (
None of the differences were statistically different between g
CI  confidence interval.eta-blocker initiation in patients with a recent episode ofecompensated HF. This recommendation was based on a
oncern that early negative hemodynamic effects of beta-
lockers may worsen short-term patient outcomes. Based on
he IMPACT-HF data, as well as recently published
ubgroup analyses from COPERNICUS, there is no evi-
ence that carvedilol initiation predischarge is associated
ith worsening HF symptoms or other adverse outcomes
15).
The patients studied in the IMPACT-HF trial are
epresentative of the typical patient admitted for worsening
F and can be characterized as “wet” (evidence of conges-
ion) and “warm” (no clinical evidence of a low-output state)
16). On admission, the patients had evidence of volume
verload. These symptoms improved but had not com-
letely resolved by the time of randomization. These pa-
ients are similar to both the OPTIME-CHF and AD-
ERE populations (7,17). The IMPACT-HF data do not
lter the recommendation that patients not be volume
verloaded when initiating beta-blockade, but rather they
ndicate that the presence of some evidence of volume
verload need not preclude initiation at appropriate low
oses. Patients presenting with low output states requiring
notropic support at the time of randomization were ex-
luded from the IMPACT-HF trial, and these findings
hould not be extrapolated to that group. However, this
atient type accounts for a small percentage of patients
dmitted with HF, representing only 1% of the population
n ADHERE.
The IMPACT-HF trial was an open-label study, which
ntroduces investigator bias in the results. The design of the
tudy precluded the use of blinding techniques. The bias was
idirectional in both groups. The predischarge carvedilol ini-
iation group may have been adversely biased to have a higher
eta-blocker withdrawal rate and fewer titration attempts
ecause the patients had recently experienced HF decompen-
ation. Conversely, this group could have been favorably biased
o achieve higher beta-blocker doses because they were initi-
ted on therapy sooner. Similarly, in the postdischarge
hysician-discretion group one would expect that the bias
ould have favorably increased the use of beta-blockers because
f physician awareness of the study, and it may have favorably
iased the tolerability because patients were initiated on beta-
lockers a median of 17 days postdischarge when they were
iation
e
Physician-Discretion
Postdischarge
Initiation
n  178
95% CI for
Difference in
Proportions*
82 (46.1) 0.0959, 0.1091
8 (4.5) 0.0272, 0.0522
45 (25.3) 0.0519, 0.1228
7 (3.9) 0.0314, 0.0452
56 (31.5) 0.0888, 0.1018
48 (27) 0.0577, 0.1213
*Difference  Physician discretion-carvedilol initiation.l Init
charg
185
45.4)
3.2)
21.7)
3.2)
30.8)
23.8)
roups.
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Carvedilol in Heart Failure Predischarge May 5, 2004:1534–41ore likely to be stable and tolerate therapy. The rate of
ospitalization was higher in the post-discharge initiation
roup, and it is possible that rehospitalization influenced the
ower rate of beta-blocker use in this group. However, in the
ame way that rehospitalization might cause fewer patients to
e initiated in the post-discharge group, rehospitalization
ight also cause more patients in the pre-discharge group to be
iscontinued, an action that was not observed. Finally, the
MPACT-HF trial had a follow-up period of 60 days, and
nitiation or continuation beyond this time point was not
ssessed.
The IMPACT-HF trial provides the first data demon-
trating that a strategy of predischarge beta-blocker
igure 2. (A) Kaplan-Meier curve depicting time to death  rehospitaliza
nscheduled visit for heart failure,50% increase in oral diuretic therapy, a
herapy with diuretics, inotropes, inodilators, or other vasoactive agents wit
roup; dashed lines  physician-discretion postdischarge initiation groupnitiation effectively improves the use of beta-blockers at 60
ays without increasing the risk of side effects or length of
nitial hospital stay in the population studied. This finding
s of significant clinical importance because it allows patients
o be initiated on lifesaving therapies earlier. This exposes
hem to the protective benefits of therapy sooner, and it
ncreases the overall likelihood that they will be treated with
he lifesaving therapy of beta-blockade. Both of these
actors have important implications for the long-term care
f the HF patient. These data also reveal the persistently
igh short-term event rate among HF patients and under-
core the urgent need to identify new treatment strategies
or this population.
B) Kaplan-Meier curve depicting time to death, recurrent hospitalization,
n of new oral diuretic therapy excluding spironolactone, or any intravenous
days post-randomization. Solid lines  predischarge carvedilol initiation
 hazard ratio.tion. (
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PPENDIX
or a list of the Steering Committee, Data and Safety
onitoring Board, Investigators, and Duke Clinical Re-
earch Institute Coordinating Center, please see the May 5,
004, issue of JACC at www.cardiosource.com/jacc.html.
